References
1. Santulli P., et al. Oligo-anovulation is not a rarer feature in women with documented endometriosis. Fertil Steril. 2018; 110 (5): 941-8.
2. Clinical guidelines. Endometriosis Ministry of Health of the Russian Federation. ID: КР259. Moscow, 2016. (in Russian)
3. Bernuit D., et al. Female perspectives on endometriosis: findings from the uterine bleeding and pain women’s research study. J Endometrios. 2011; 3 (2): 73-85.
4. Dunselman G.A., et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29 (3): 400-12.
5. Radzinsky V.E., Fuks A.M., eds. Gynecology: textbook. 2nd ed., Rev. and add. Moscow: GEOTAR-Media, 2019.1104 p. ISBN 978-5-9704-4413-9. (in Russian)
6. Culley L., Law C., Hudson N., et al. A qualitative study of the impact of endometriosis on male partners. Hum Reprod. 2017; 32 (8): 1667-73.
7. Saraswat L., Ayansina D., Cooper K., Bhattacharya S., Horne A., Bhattacharya S. Impact of endometriosis on risk of further gynaecological surgery and cancer: a national cohort study. BJOG. 2017; 125 (1): 64-72.
8. Sagsveen M., Farmer J.E., Prentice A., Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database of Systematic Reviews. 2003.
9. Brown J., et al. Cochrane Database of Systematic Reviews 2018, Issue 5.
10. Winkel C.A., Scialli A.R. Medical and surgical therapies for pain associated with endometriosis. J Womens Health Gend Based Med. 2001; 10 (2): 137-62.
11. Dubrovina S.O., Berlim Yu.D. Drug treatment for endometriosis-related pain. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2019; 2: 34-40. (in Russian)
12. Patel B.G., Rudnicki M., Yu J., et al. Progesterone resistance in endometriosis: origins, consequences and interventions. Acta Obstet Gynecol Scand. 2017; 96 (6): 623-632.
13. Attia G.R., Zeitoun K., Edwards D., et al. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000; 85: 2897-902.
14. Burney R.O., Talbi S., Hamilton A.E., et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007; 148: 3814-26.
15. Ober W.B., Bernstein J. Observations on the endometrium and ovary in the newborn. Pediatrics. 1955; 16: 445-60.
16. Guo S.W. Nuclear factor-KB (NF-kB): An unsuspected major culprit in the pathogenesis of endometriosis that is still at large? Gynecol Obstet Invest. 2007; 63: 71-97.
17. Bruner-Tran K.L., Ding T., Osteen K.G. Dioxin and endometrial progesterone resistance. Semin Reprod Med. 2010; 28: 59-68.
18. Zhao D., Pritts E.A., Chao V.A. et al. Dioxin stimulates RANTES expression in an in-vitro model of endometriosis. Mol Hum Reprod. 2002; 8: 849-54.
19. Nayyar T., Bruner-Tran K.L., Piestrzeniewicz-Ulanska D., et al. Developmental exposure of mice to TCDD elicits a similar uterine phenotype in adult animals as observed in women with endometriosis. Reprod Toxicol. 2007; 23: 326-36.
20. Hayashi A., Tanabe A., Kawabe S. et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovarian Res. 2012; 5: 31.
21. McCormack P.L. Dienogest. A Review of its Use in the Treatment of Endometriosis. Drugs. 2010; 70 (16): 2073-88.
22. Sasagawa S., Shimizu Y., Kami H., et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids. 2008; 73 (2): 222-31.
23. Mochida Pharmaceutical Co. Ltd. Drug interview form: DINagest Tab. 1 mg (dienogest film-coated tablets) for the treatment of endometriosis. 2007: 1-82.
24. Foster R.H., Wilde M.I. Dienogest. Drugs. 1998; 56 (5): 825-33; discussion 83-5.
25. Medicines Evaluation Board (Netherlands). Visanne (dienogest 2 mg tablet): summary of product characteristics [online]. Available from URL: http://db.cbg-meb.nl/IBteksten/h104058.pdf
26. Strowitzki T., Faustmann T., Gerlinger C., et al. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010; 151 (2): 193-198.
27. Hirata T., Izumi G., Takamura, et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol. 2014; 30 (10): 726-9.
28. Harada T., Momoeda M., Taketani Y., et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis: a randomized, doubleblind, multicenter, controlled trial. Fertil Steril. 2009; 91 (3): 675-81.
29. Strowitzki T., Marr J., Gerlinger C., et al. Dienogest is as effective as leupro-lide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010; 25 (3): 633-41.
30. Kitawaki J., Kusuki I., Yamanaka K., et al. Maintenance therapy with dieno-gest following gonadotropinreleasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur J Obstet Gynecol Reprod Biol. 2011; 157 (2): 212-6.
31. Maiorana A., Incandel, D., Parazzini F., et al. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch Gynecol Obstet. 2017: 296 (3): 429-33.
32. Kohler G., Faustmann T.A., Gerlinger C., et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis. Int J Gynaecol Obstet. 2010; 108: 21-5.
33. Kohler G., Goretzlehner G., Amon I. Therapy of endometriosis with dienogest. Zentralbl Gynakol. 1987; 109: 795-801.
34. Cosson M., Querleu D., Donnez J., et al. Dienogest is as effective as trip-torelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril. 2002; 77: 684-92.
35. Momoeda M., Taketani Y. A randomized, double-blind, multicenter, parallel, dose-response study of dienogest in patients with endometriosis [in Japanese]. Jpn Pharmacol Ther. 2007; 35: 769-83.
36. Sugimoto K., Nagata C., Hayashi H. et al. Use of dienogest over 53 weeks for the treatment of endometriosis. J Obstet Gynaecol Res. 2015; 41(12): 1921-6.
37. Takaesu Y., Nishi H., Kojima J., et al. Dienogest compared with gonadotropinreleasing hormone agonist after conservative surgery for endometriosis. J Obstet Gynaecol Res. 2016; 42 (9): 1152-8.
38. Lee S.R., Yi K.W., Song J.Y., et al. Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma. Reprod Sci. 2017; 25 (3): 341-6.
39. Abdou A.M., Ammar I.M.M., Alnemr A.A.A., et al. Dienogest Versus Leuprolide Acetate for Recurrent Pelvic Pain Following Laparoscopic Treatment of Endometriosis. J. Obstet Gynecol India. 2018; 68 (4): 306-13.
40. Agarwa S., Fraser M.A., Chen I., et al. Dienogest for the treatment of deep endometriosis: Case report and literature review. J Obstet Gynaecol Res 2014: 41 (2): 309-13.
41. Leonardo-Pinto J.P., Benetti-Pinto C.L., Yela D.A. When solving dyspareunia is not enough to restore sexual function in women with deep infiltrating endometriosis treated with dienogest. J Sex Marital Ther. 2018; 1-14.
42. Medicines Evaluation Board (Netherlands). Public assessment report of the Medicines Evaluation Board in the Netherlands: Visanne (dienogest), tablets, 2 mg. 2010 Mar [online]. Available from URL: http://db.cbg-meb.nl/Pars/h104058.pdf
43. Strowitzki T., Faustmann T., Gerlinger C., et al. Safety and tolerability of di-enogest in endometriosis: pooled analysis from the European clinical study program. Int J Womens Health. 2015; 7: 393-401.
44. Petraglia F., Hornung D., Seitz C., et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012; 285 (1): 167-73.
45. Techatraisak K., Hestiantoro A., Ruey S., et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under real-life clinical practice. BMC Women’s Health, 2019; 19 (1): 68.